CLINICAL TRIALS PROFILE FOR RITALIN LA

All Clinical Trials for RITALIN LA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00018863 ↗	Treatment of Attention Deficit Hyperactivity Disorder in Preschool-Age Children (PATS)	Completed	National Institute of Mental Health (NIMH)	Phase 3	2001-04-01	This research focuses on the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in very young children. The medication being used is methylphenidate (Ritalin); it is being studied to determine its safety and how well it works to treat ADHD in preschool-age children (3-5.5 year olds).
NCT00018863 ↗	Treatment of Attention Deficit Hyperactivity Disorder in Preschool-Age Children (PATS)	Completed	New York State Psychiatric Institute	Phase 3	2001-04-01	This research focuses on the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in very young children. The medication being used is methylphenidate (Ritalin); it is being studied to determine its safety and how well it works to treat ADHD in preschool-age children (3-5.5 year olds).
NCT00025779 ↗	Methylphenidate in Children and Adolescents With Pervasive Developmental Disorders	Completed	National Institute of Mental Health (NIMH)	N/A	2001-10-01	This study will evaluate the efficacy and safety of methylphenidate for treating hyperactivity, impulsiveness, and distractibility in 60 children and adolescents with Pervasive Developmental Disorders (PDD). Methylphenidate (Ritalin)is approved by the Food and Drug Administration for the treatment of children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD). Data supporting its safety and effectiveness in treating ADHD symptoms in PDD are limited. Children and adolescents who do not show a positive response to methylphenidate will be invited to participate in a pilot study of the non-stimulant medication guanfacine (Tenex).
NCT00129467 ↗	Methylphenidate for Depressed Cancer Patients Receiving Palliative Care	Completed	Oregon Health and Science University	N/A	2005-02-01	The purpose of this study is to determine whether methylphenidate is an effective treatment for depression and to document the safety and tolerability of methylphenidate in combination with an Selective Serotonin Reuptake Inhibitor (SSRI) in SSRI treated, terminally ill, hospice and palliative care cancer patients. The investigators hypothesize that depressed hospice and palliative care patients will be more likely to have a 50% reduction in scores on a clinical measure of depression after treatment with Methylphenidate plus an SSRI compared to those patients who are taking a placebo plus an SSRI.
NCT00129467 ↗	Methylphenidate for Depressed Cancer Patients Receiving Palliative Care	Completed	US Department of Veterans Affairs	N/A	2005-02-01	The purpose of this study is to determine whether methylphenidate is an effective treatment for depression and to document the safety and tolerability of methylphenidate in combination with an Selective Serotonin Reuptake Inhibitor (SSRI) in SSRI treated, terminally ill, hospice and palliative care cancer patients. The investigators hypothesize that depressed hospice and palliative care patients will be more likely to have a 50% reduction in scores on a clinical measure of depression after treatment with Methylphenidate plus an SSRI compared to those patients who are taking a placebo plus an SSRI.
NCT00129467 ↗	Methylphenidate for Depressed Cancer Patients Receiving Palliative Care	Completed	VA Office of Research and Development	N/A	2005-02-01	The purpose of this study is to determine whether methylphenidate is an effective treatment for depression and to document the safety and tolerability of methylphenidate in combination with an Selective Serotonin Reuptake Inhibitor (SSRI) in SSRI treated, terminally ill, hospice and palliative care cancer patients. The investigators hypothesize that depressed hospice and palliative care patients will be more likely to have a 50% reduction in scores on a clinical measure of depression after treatment with Methylphenidate plus an SSRI compared to those patients who are taking a placebo plus an SSRI.
NCT00136734 ↗	Methylphenidate Treatment for Cocaine Abuse and ADHD - 1	Completed	National Institute on Drug Abuse (NIDA)	Phase 1	1998-04-01	Many cocaine dependent individuals are also diagnosed with Attention Deficit Hyperactivity Disorder (ADHD). Methylphenidate (Ritalin) is currently approved to treat individuals diagnosed with ADHD. The purpose of this study is to determine the effectiveness of methylphenidate in treating ADHD symptoms in cocaine dependent individuals.

Clinical Trial Conditions for RITALIN LA

Condition Name

Condition Name for RITALIN LA
Intervention	Trials
Attention Deficit Hyperactivity Disorder	26
Healthy	11
Attention Deficit Disorder With Hyperactivity	7
Apathy	5

Condition MeSH

Condition MeSH for RITALIN LA
Intervention	Trials
Attention Deficit Disorder with Hyperactivity	47
Hyperkinesis	35
Disease	24
Fatigue	9

Clinical Trial Locations for RITALIN LA

Trials by Country

Trials by Country for RITALIN LA
Location	Trials
United States	105
Israel	18
Canada	11
Switzerland	4
Netherlands	4

Trials by US State

Trials by US State for RITALIN LA
Location	Trials
California	13
Texas	10
Massachusetts	10
Maryland	9
Ohio	8

Clinical Trial Progress for RITALIN LA

Clinical Trial Phase

Clinical Trial Phase for RITALIN LA
Clinical Trial Phase	Trials
Phase 4	37
Phase 3	14
Phase 2/Phase 3	5

Clinical Trial Status

Clinical Trial Status for RITALIN LA
Clinical Trial Phase	Trials
Completed	67
Unknown status	20
Terminated	13

Clinical Trial Sponsors for RITALIN LA

Sponsor Name

Sponsor Name for RITALIN LA
Sponsor	Trials
Massachusetts General Hospital	8
National Institute of Mental Health (NIMH)	8
Shalvata Mental Health Center	6

Sponsor Type

Sponsor Type for RITALIN LA
Sponsor	Trials
Other	164
NIH	23
Industry	15